Treatment of drug-susceptible tuberculosis among people living with human immunodeficiency virus infection: an update.

ABSTRACT:

Purpose of review

The present review describes recent advances in the treatment of drug-susceptible tuberculosis (DS-TB) among people living with human immunodeficiency virus (PLWH).

Recent findings

Higher than standard rifampicin doses (>10 mg/kg/day) are well tolerated and have improved sterilizing activity. Standard pyrazinamide doses may result in low drug exposures; modeling reveals that higher doses (>25 mg/kg/day) may be required to reach target levels, although safety is unknown. Four-month fluoroquinolone-containing regimens are not recommended in the 2017 World Health Organization DS-TB treatment guidelines. These guidelines also recommend fixed-dose combination (FDC) therapy over single drug formulations based on patient preference, though FDC is not associated wi

SUBMITTER: Pettit AC 

PROVIDER: S-EPMC6389504 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature